18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with

Recruiting

18 years - 99 years

Male

Phase 1

30 participants needed

1 Location

Brief description of study

The research study is being conducted to test how a new radioactive imaging drug called 18F-Fluorthanatrace (18F-FTT) can be used to take computerized pictures of places in the body where prostate cancer has spread (metastasized). The pictures will be taken before, and optionally after treatment. 18F-FTT is a drug used with an imaging test called Positron Emission Tomography/Computed Tomography (PET/CT).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Metastatic Prostate Cancer
Age: 18 years - 99 years
Gender: Male

Males. over age 18, diagnoses with Metastatic Prostate Cancer

Updated on 04 Aug 2024. Study ID: 849671

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

18F-FluorThanatrace positron emission tomography (PET/CT) in Patients with Metastatic Prostate Cancer

Brief description of study

Eligibility of study

Find a site

Interested in the study